There have been recent major developments in the brain-computer interface track.

Elon Musk's Neuralink officially announced that large-scale mass production will begin in 2026, along with a comprehensive shift toward automated surgical procedures. This is no small feat—it marks the official transition of brain-computer interfaces from clinical trials into the commercialization era. How strong will the industry chain's response be? Expect a direct surge in demand for hardware components such as surgical robots, high-precision electrodes, and biocompatible materials; on the software side, AI algorithms and signal processing chips will also take off.

Domestic listed companies have significant opportunities in this wave. Those with layouts in core hardware, medical scenario transformation, and algorithm platforms will become more prominent.

**Who has the best chance? An overview of 18 companies**

**iFlytek**
A leading domestic AI company, has been working on brain-computer interfaces for several years, holding 303 related patents. Their EEG-speech joint decoding framework is excellent, with emotion recognition accuracy reaching 92.3%. The API is already being used for ALS patients, enabling communication. They have entered the national innovative medical device green channel, which speeds up approval processes.

**Sino Brain**
A leader in neurological medical specialties, performed the world's first interventional brain-computer interface human trial. Their self-developed Rosa robotic electrode implantation achieves an accuracy of 0.1 millimeters, top industry level. In 2025, they expect over 200 surgeries, with single-episode epilepsy treatment charging 500,000 RMB, and revenue doubling by 2026. The growth curve is steep.

**Innovative Medical**
Through equity participation in Boring Brain, they are developing invasive brain-computer technology with a technical approach closely aligned with Neuralink. Clinical projects have advanced to Phase III. They are also collaborating with medical institutions to develop communication aids for ALS patients, with smooth progress.

**Hanwei Technology**
Subsidiary Suzhou Nengsi Da has developed a 0.1mm ultra-flexible EEG sensor, costing half as much as American products. One of the thinnest flexible EEG sensors globally, representing a technical advantage. They won the "Key Devices for Brain-Computer Interface" project from the Ministry of Industry and Information Technology and provide technical support to companies like Huawei, with good channels.

**Xiangyu Medical**
A domestic leader in rehabilitation medical devices, accelerating brain-computer interface commercialization. They have obtained registration for brain signal collection devices and plan to launch 30 new products by 2026, aiming for revenue over 100 million RMB. Their products are already in 700 top-tier hospitals, with plans to reach 1,500 by 2026. The expansion pace is rapid.

**Century Huatong**
Exploring "game + brain-computer" integration through its subsidiary Shengqu Games. A brain-computer interface game developed in cooperation with Zhejiang University is already in internal testing. They are also investing in brain-computer interface technology R&D, aiming to find applications in medical rehabilitation, with a promising approach.

**Yanshan Technology**
Engaged in full industry chain layout, covering high-precision electrodes, signal processing chips, and AI algorithms. Their non-invasive brain-computer devices are already used in education, security, and other fields. The coverage is broad.

**Hige Communication**
Leveraging military technology accumulation, they are transferring satellite communication signal processing technology into the brain-computer interface field. Their developed signal processing modules have leading anti-interference capabilities internationally. Small batch applications are already in medical and industrial control scenarios. They are using existing advantages to explore new markets.

**Lepu Medical**
A leading cardiovascular medical device company, now expanding into brain-computer interface applications in rehabilitation. Their brain-controlled exoskeleton system has entered clinical trials, with plans to include related products in the medical insurance catalog by 2026. Insurance coverage will be a growth booster.

**Tom Cat**
Pioneering in entertainment, has completed technical validation for "thought-controlled" games, planning to launch the first commercial product in 2026. They are also exploring brain-computer interface applications in children's education. Consumer-grade applications have huge potential.

**Nanjing Panda**
Features multi-scenario technology exploration. Their medical brain-controlled exoskeleton system has helped restore motor functions for spinal cord injury patients; their industrial "EEG + eye movement" multimodal control system can precisely operate robotic arms with signal response delays below 50 milliseconds. They integrate medical and engineering fields comprehensively.

**Meihui Medical**
A leading enterprise in medical device precision components, with deep technical accumulation in cochlear implants. Applying this experience to invasive brain-computer interface implant materials and biocompatibility, forming advantages. They are already a core supplier for several international brain-computer interface companies. This is a "selling water" type business.

**Yingqu Technology**
Strong in smart hardware manufacturing, providing OEM services for domestic and international brain-computer interface companies. Their automated production lines can achieve high-precision assembly of electrode components. They are also exploring brain-computer interface applications in smart home fields. OEM model offers stable returns.

**UCloud**
Provides cloud computing services for brain-computer interface companies, with a dedicated AI training platform supporting large-scale real-time EEG data processing and analysis. They have established collaborations with multiple research institutions to promote algorithm optimization. Cloud computing has high entry barriers and strong stickiness.

**Lihua Kechuang**
Their technology incubator has invested in 12 brain-computer interface startups, covering the entire industry chain from core hardware to application scenarios. They also support technology transfer and clinical trials for resident companies. Sitting at a key node in the industry.

**Daoshi Technology**
Specializes in polymer materials, providing high-performance packaging materials for brain-computer interface devices. Their biocompatible materials have passed third-party testing and are already in mass production. Material suppliers will play an increasingly important role.

**StarNet Ruijie**
Transforms network equipment technology advantages into low-latency, high-reliability brain-computer interface data transmission systems. Products are already commercialized in medical and industrial scenarios, supporting multi-device coordination. Communication infrastructure will be crucial in brain-computer interfaces.

**Prite**
Focuses on polymer material R&D, with lightweight, high-strength materials used in brain-computer interface device shells and structural parts. Also exploring biodegradable materials, reserving solutions for future implantable devices. In the long term, biodegradable materials have great potential.

**How to view this opportunity?**

Neuralink's mass production plan accelerates the brain-computer interface industry from three dimensions—technology validation, capital attention, and policy support. Domestic companies have already built technical barriers in core hardware, medical scenario transformation, and algorithm platforms. Once the industry fully commercializes, many companies will benefit.

Investment logic can focus on three lines:

The first is medical companies with technical paths close to Neuralink and leading clinical progress. These companies are ahead, with higher chances of their products being included in medical insurance.

The second is "selling water" companies that master core hardware. Electrodes, materials, signal processing chips—regardless of how competitive the industry gets, these companies will have opportunities.

The third is companies that have already commercialized in specific application scenarios. For example, products in gaming, education, and rehabilitation segments will scale faster later.

As brain-computer interfaces shift from science fiction to reality, this cycle will be faster than expected.